Results 141 to 150 of about 713,403 (256)

Case‐Based Immunology: B Cells and Systemic Sclerosis Interstitial Lung Disease

open access: yesArthritis &Rheumatology, EarlyView.
Interstitial lung disease (ILD) is an important complication of systemic sclerosis (SSc), with high mortality and morbidity. Recent clinical studies in SSc‐ILD have led to US Food and Drug Administration–approved therapies in SSc‐ILD. Importantly, evidence from these studies has been extrapolated to guide management of ILDs of other systemic autoimmune
Nina Goldman   +2 more
wiley   +1 more source

Association of Abatacept With Lower Mortality Risk Compared to Rituximab in Rheumatoid Arthritis–Associated Interstitial Lung Disease: An Emulated Target Trial

open access: yesArthritis &Rheumatology, EarlyView.
Objective The optimal treatment strategy for rheumatoid arthritis–associated interstitial lung disease (RA‐ILD) remains uncertain, and direct comparative data between biologics are limited. This study aimed to evaluate the effectiveness and safety of abatacept compared with rituximab in patients with RA‐ILD.
Po‐Cheng Shih   +3 more
wiley   +1 more source

Reactive Oxygen Species–Induced Modifications of Fibrin Clots as a Link Between Immune Responses and Atherothrombosis in Systemic Lupus Erythematosus

open access: yesArthritis &Rheumatology, EarlyView.
Objective Cardiovascular events are major determinants of morbidity and mortality in systemic lupus erythematosus (SLE), particularly in patients with renal involvement. Although oxidative stress has been implicated in driving vascular and renal damage in SLE, the specific mechanisms remain unclear.
Matteo Becatti   +13 more
wiley   +1 more source

Telomere Length of Peripheral Blood Leukocytes Predicts Disease Severity and Worse Survival in Systemic Sclerosis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Peripheral blood leukocyte telomere length (PBL‐TL) shortening is associated with systemic sclerosis–related interstitial lung disease (SSc‐ILD). However, its association with other organ involvement, disease severity, and survival remains unclear.
Monica M. Yang   +6 more
wiley   +1 more source

Diagnostic Implications and Correlates of Plasma Adenosine Deaminase 2 Activity and ADA2 Variants

open access: yesArthritis &Rheumatology, EarlyView.
Objective Deficiency of adenosine deaminase 2 (DADA2) is a monogenic autoinflammatory disease manifested as polyarteritis nodosa, stroke, and bone marrow failure. Leveraging an international cohort of 200 DADA2 cases, we aimed to characterize the diagnostic utility of a plasma ADA2 enzyme activity assay and understand the implications of residual ADA2 ...
Jian Yue   +55 more
wiley   +1 more source

Romosozumab and Denosumab Combination Therapy After Denosumab in Postmenopausal Osteoporosis

open access: yesArthritis &Rheumatology, Accepted Article.
Background Transition from long‐term denosumab to PTH‐analogs or romosozumab might expose patients to the risk of the so‐called rebound phenomenon. Adding romosozumab to denosumab might represent an option in patients experiencing a fracture while on denosumab.
Giovanni Adami   +10 more
wiley   +1 more source

Defining Optimally Safe and Effective Blood Levels of Hydroxychloroquine in Lupus: An Important Step toward Precision Drug Monitoring

open access: yesArthritis &Rheumatology, Accepted Article.
Background Using hydroxychloroquine (HCQ) dose of 5 mg/kg/day in systemic lupus erythematosus (SLE) is associated with a higher risk of flares; HCQ blood level monitoring could be a better way to adjust HCQ dose. We studied the upper threshold for a reference range of HCQ levels to inform routine monitoring.
Shivani Garg   +42 more
wiley   +1 more source

Nationwide temporal trends in adverse pregnancy outcomes and treatments in systemic lupus erythematosus pregnancy over two decades in Sweden

open access: yesArthritis &Rheumatology, Accepted Article.
Objective This nationwide descriptive study examined temporal trends in adverse pregnancy outcomes (APOs) and treatments in systemic lupus erythematosus (SLE) pregnancies in Sweden over 2003‐2022. Methods Using nationwide Swedish registers, we identified 1,417 pregnancies of women with prevalent SLE and delivery dates in 2003‐2022, and matched them to ...
Ngoc V. Nguyen   +6 more
wiley   +1 more source

Risk factors for relapse in ANCA‐associated vasculitis among patients with relapse after induction of remission with rituximab

open access: yesArthritis &Rheumatology, Accepted Article.
Objective To determine risk factors for relapse of ANCA‐associated vasculitis (AAV) after re‐induction of remission with rituximab and discontinuation of maintenance therapy. Methods This is a post‐hoc analysis of the RITAZAREM clinical trial. Patients 15 years or older with AAV and a positive test for anti‐proteinase‐3 (PR3‐) or anti‐myeloperoxidase ...
Ellen Romich   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy